5 results match your criteria: "Finland (P.P.-E.); and South Karelia Central Hospital[Affiliation]"
Magnetic Resonance Imaging in the Assessment of the Risk of Sudden Death in Cardiac Sarcoidosis: What Is Extensive or Significant Late Gadolinium Enhancement?
Circ Arrhythm Electrophysiol
December 2024
Heart and Lung Center (P.P., J.L., D.V., H.M., P.S., H.-K.N., M.K.).
Background: Cardiac sarcoidosis involves a significant but difficult-to-define risk of sudden cardiac death (SCD). Current guidelines recommend consideration of an implantable cardioverter defibrillator for patients with extensive or significant myocardial late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging. However, extensive/significant LGE is not defined.
View Article and Find Full Text PDFEnd-Stage Heart Failure in Cardiac Sarcoidosis.
Circulation
March 2024
Heart and Lung Center (D.V., P.P., J.L., P.S., M.K.), Helsinki University Hospital and University of Helsinki, , Finland.
Incidence of Sudden Cardiac Death and Life-Threatening Arrhythmias in Clinically Manifest Cardiac Sarcoidosis With and Without Current Indications for an Implantable Cardioverter Defibrillator.
Circulation
September 2022
Heart and Lung Center (H.-K.N., P.P., J.L., K.E., M.N., M.K.), Helsinki University Hospital and University of Helsinki, Finland.
Background: Cardiac sarcoidosis (CS) predisposes to sudden cardiac death (SCD). Guidelines for implantable cardioverter defibrillators (ICDs) in CS have been issued by the Heart Rhythm Society in 2014 and the American College of Cardiology/American Heart Association/Heart Rhythm Society consortium in 2017. How well they discriminate high from low risk remains unknown.
View Article and Find Full Text PDFOutcome of Cardiac Sarcoidosis Presenting With High-Grade Atrioventricular Block.
Circ Arrhythm Electrophysiol
August 2018
Heart and Lung Center (H.-K.N., J.L., K.E., R.K., P.S., M.K.).
Background: Symptomatic high-grade atrioventricular block (AVB) is the most common and often the only presenting manifestation (lone AVB) of cardiac sarcoidosis. Implantation of an intracardiac cardioverter defibrillator instead of a pacemaker is recommended, but the true risk of fatal arrhythmia, one incident to lone AVB in particular, remains poorly known.
Methods: We used Myocardial Inflammatory Diseases in Finland Study Group Registry to analyze the presentations, left ventricular (LV) function, pacemaker therapy, and ventricular arrhythmias in cardiac sarcoidosis.
Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study.
Circulation
February 2015
From the Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland (R.K., J.L., M.K.); Heart Center, Turku University Hospital, Turku, Finland (J.A., T.V.); Heart Center, Kuopio University Hospital, Kuopio, Finland (H.M.); Medical Research Center Oulu, University and University Hospital of Oulu, Oulu, Finland (K.Y., K.K.); Heart Hospital, Tampere University Hospital, Tampere, Finland (S.T., P.H.); Päijät-Häme Central Hospital, Lahti, Finland (T.K.); Central Finland Central Hospital, Jyväskylä, Finland (J.K.); South Ostrobothnia Central Hospital, Seinäjoki, Finland (M.P.); Vaasa Central Hospital, Vaasa, Finland (P.P.-E.); and South Karelia Central Hospital, Lappeenranta, Finland (S.U.).
Background: This study was designed to assess the epidemiology, characteristics, and outcome of cardiac sarcoidosis (CS) in Finland.
Methods And Results: We identified in retrospect all adult (>18 years of age) patients diagnosed with histologically confirmed CS in Finland between 1988 and 2012. A total of 110 patients (71 women) 51±9 years of age (mean±SD) were found and followed up for outcome events to the end of 2013.